cogstate to move...... nice announcement....should start to move...

cogstate to move...... nice announcement....should start to move (imho)...


CogState signs deal with US Centers
for Disease Control (CDC) for HIV Dementia Trial
Melbourne, August 13, 2004 - CogState Ltd (ASX:CGS) has signed a deal with the US
Government agency - The Centers for Disease Control and Prevention (CDC) in Atlanta,
Georgia to use the CogState computer-based cognitive test in a large prospective trial in
patients with HIV to spot early signs of HIV-related dementia. The CDC - the world’s largest
federal agency for disease prevention and control As nearly 40% of HIV patients show a decline
in brain function characterized by loss of initiative and motivation to cope with the demands of
everyday life, early identification of these individuals could result in improved quality-of-life.
CogState Ltd. CEO, Dr. Peter Bick commented "It is hard to overstate the importance of this win
for the company because US government agencies are obligated to first review US products. In
searching for a the best tool to accurately measure changes in brain function (cognition) over
time, and which had no cultural or language bias, the CDC chose CogState, demonstrating to
the world that our technology is superior to anything available in the US. The $21,000 value of
the deal is useful, but the true value is in the credibility it bestows for us in the largest market in
the world, the US".
“The sentiment of the CDC was recently echoed by Schutt Sports, the #1 gridiron football
manufacturer in the US, who choose CogState as a partner to make Concussion Sentinel™
available to every high school and college in the US. We are a small but these deals point-out
to the discerning that we are on the right track to build a robust sales pipeline” added Dr. Bick.
About CogState
CogState Ltd. was established in 1999 with headquarters in Melbourne, Australia. In February
2004 the company listed on the Australian Stock Exchange (ASX) as “CGS.” The company
specializes in neuroscience, particularly in the development and commercialization of computerbased
tests for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease and
concussion-related injury. A division of the company, CogSport, marketed in the U.S. as
Concussion Sentinel, is a novel concussion management tool developed to aid physicians in
making confident return-to-play decisions after an athlete has suffered a concussion.
Concussion Sentinel is applicable for use by sporting organizations, medical professionals, and
parents/athletes and provides rapid measurement of cognitive function. Other divisions of the
company focus on providing computer-based measurement tools to pharmaceutical companies
for use during clinical trials.
For more information please visit: www.cogstate.com